Erich Mounce, chief operating officer, OneOncology, discusses how payment models like the Oncology Care Model are changing the way oncologists practice, as well as what practices should prioritize when looking to participate in a payment model.
Erich Mounce, chief operating officer, OneOncology, discusses how payment models like the Oncology Care Model are changing the way oncologists practice, as well as what practices should prioritize when looking to participate in a payment model.
Transcript
How are payment models, such as the Oncology Care Model, changing the way community oncologists practice?
I think for the better. From my perspective, that standardization of payment models is allowing us to drive the same kind of care based on evidence. For example, it send to be that medical oncologists could only use 1 or 2 drugs in their tool chest. Not all of those drugs would work on those cancers, but they’d use them anyway because there was a 50/50 chance or a 60/40 chance that they would work. Now, with targeted medicine, that allows us to target the right drugs and then allows us to really work on value-based care, Oncology Care Model standardization to use a care model that processes through with the patient’s care.
It’s not just a regimen. For us at OneOncology, a care pathway or a care model that goes within a bundled payment or Oncology Payment Model is also really soup to nuts. It is, once you’re diagnosed, when do you see a genetic counselor? When do you see the surgeon? When do you get the CT [computerized tomography] scan? When do you get the PET [positron emission tomography] scan? When do you have surgery? When do you have chemo? It’s not just what drugs are used, and for me, that’s really a challenging step that gives a lot of opportunity to be successful with patient care in the future.
When looking to participate in a payment model, what should practices prioritize?
There’s lots of variations out there. The most important thing is to find a model that’s passionate about patient care and about the delivery of that care, not just commoditizing drug prices or supply prices. It’s really about making sure you have somebody that believes the same way that a physician did when they went to school and now that they’re a medical oncologist about how to treat the patient right and everything else follows that.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More